CTRI/2021/04/032648进行中（未招募）3 期
To evaluate the efficacy and safety of triple therapy with nicorandil, aspirin and atorvastatin in patients with SARS-CoV -2 infection: randomized controlled trial (NAAC trial)â?? - NAAC
Dr Ambudhar Sharma0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age >18years
- •A person with laboratory confirmation of covid -19, irrespective of signs and symptoms,
- •Patients with moderate clinical severity(pneumonia with no signs of severe disease) and severe (severe pneumonia and mild ARDS) requiring hospital admission , Consenting to participate for the trial
排除标准
- •Documented significant liver disease / dysfunction (AST/ALT > 240), Myopathy and Rhabdomyolysis (CPK > 5x normal) , Allergy or intolerance to statins , Allergy or intolerance to aspirin , Patients taking the following medications: cyclosporine, HIV protease inhibitors, hepatitis C protease inhibitor, telaprevir, fibric acid derivatives (gemfibrozil), niacin, azole antifungals (itraconazole, ketoconazole) clarithromycin and colchicine , Prior statin use (within 30 days), Prior aspirin use (within 30 days) , History of active GI bleeding in past three months
- •,Coagulopathy , Thrombocytopenia (Platelet count < 100000/ dl), Pregnancy, active breast-feeding , Patient unable to take oral or nasogastric medications
- •,Moderate and severe ARDS, renal dysfunction, altered mental status, shock, thrombotic manifestation ,sepsis at presentation
研究者
相似试验
招募中
3 期
Evaluation of the effect of interferon beta-1b in the treatment of COVID-19IRCT20200921048786N1Dezfoul University of Medical Sciences82
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FRovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FIovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-DKovo Nordisk A/S288
已完成
2 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.Non-alcoholic steatohepatitis10019654NL-OMON47918ovo Nordisk12